BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE
7 January, 2008
TEKES FINANCES BIOTIE'S THROMBOSIS PROGRAM WITH EUR 1.7 MILLION
The Finnish Funding Agency for Technology and Innovation (Tekes) has
granted EUR 1.7 million additional funding for Biotie Therapies'
integrin alpha2beta1 inhibitor program for thrombosis. The R&D
funding granted covers drug development costs of the project from
July 2007 to December 2009.
The funding granted is in the form of loan and it covers 50 per cent
of the costs of the project. The loan will be paid to Biotie against
reported realised costs. In order to receive the full amount of
granted financing, Biotie must show a total expenditure of EUR 3.4
million in the project.
Turku, 7 January 2008
Biotie Therapies Corp.
Timo Veromaa
President and CEO
For further information, please contact:
Timo Veromaa, President and CEO, Biotie Therapies Corp.
tel. +358 2 274 8901, e-mail: timo.veromaa@biotie.com
www.biotie.com
Distribution: OMX Nordic Exchange Helsinki
Main Media